Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
IPO Year: 2020
Exchange: NASDAQ
Website: https://www.bioratherapeutics.com
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
10-Q - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
424B5 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
424B3 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
424B3 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
424B3 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
Fastest customizable press release news feed in the world
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Biora Therapeutics, a biotech company developing the first swallowable autoinjector, today announced the successful completion of its court-supervised restructuring. Through the restructuring process, Biora achieved an improved balance sheet with deleveraged debt and significant new financing to support the business going forward. Biora has emerged from the restructuring as a privately held company. "Emergence marks a new beginning for us as a leaner, stronger, well-capitalized company with a mission to revolutionize the way biologic pharmaceuticals are delivered to patients," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "W
Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. ("Biora" or the "Company"), a biotech company developing smart pill-based therapeutic platforms, today announced it has reached an agreement with certain of its prepetition creditors (the "Lenders") to provide financing to support a chapter 11 sale process, which will ultimately lead to a strengthened balance sheet and help enable it to launch its next stage of product development. To effectuate the transaction, the Company has filed a voluntary petition under chapter 11 o
Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The company will not host a conference call. "We've made much faster progress than anticipated developing a smaller BioJet device that is highly desired by pharma companies," said A
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets. Conference Call and Webcast InformationDate: Thursday, November 14, 2024Time: 4:30 PM Eastern time / 1:30 PM Pacific timeConference Call: Domestic 1-877-423-9813International 1-201-689-8573Conference ID 13749254Live Webcast: https://investors.bioratherapeutics.com/events-presentations A replay will
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 745,342 shares of the Company's common stock at an offering price of $4.025 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 745,342 shares of common stock. The warrants have an exercise price of $3.90 per share, will be exercisable upon issuance, and will expire five years following issuance. The closing
SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today is sharing progress on its development of the BioJet™ Oral Delivery Platform, which is designed to replace injection with needle-free, oral delivery, at the 14th Annual Partnership in Drug Delivery (PODD) meeting in Boston, Massachusetts. "We have now demonstrated the ability to autonomously deliver to the small intestine in canine models with our smaller, 00-size BioJet device, a size that is desired by both patients and pharma companies," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "We have agreed with existing mega-cap p
SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that Adi Mohanty, CEO of Biora Therapeutics, will present on the company's 00-size BioJet™ device at the 14th Annual Partnership Opportunities in Drug Delivery (PODD) meeting, taking place in Boston, October 28–29, 2024. "As part of the development of our clinical-ready BioJet device, we were able to reduce its size from 000 to 00, while slightly increasing the payload capacity," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "Market research indicates a strong patient preference for a 00-size device, a preference that
SAN DIEGO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will present at the 19th Annual Peptide Therapeutics Symposium, taking place virtually and in person in La Jolla, California, October 22–23, 2024. Details of the presentation are as follows: Presentation Title:Empowering Peptide Self-Administration with Needle Free Smart CapsulesDate & Time:October 22, 2024, 2:30 PM – 3:00 PM PTPresenter:Sharat Singh, PhD, Head of Research, Biora Therapeutics The Peptide Therapeutics Symposium brings together world leaders in peptide research from academia and the biopharmaceuti
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced an upcoming poster presentation at the American College of Gastroenterology (ACG) Annual Scientific Meeting, which will be held in Philadelphia, October 25–30, 2024. Biora's submission was awarded a Presidential Poster Award by the ACG Abstract Selection Committee. Each year less than 5% of accepted abstracts receive this distinction for high quality, novel, unique, and interesting research. Details of the presentation are as follows: Poster Number:P4275 Session Date:October 29, 2024 10:30 AM – 4:00 PM ET Presenting Author:Brian Feag
SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it has been awarded ISO 13485:2016 certification by TÜV SÜD America, demonstrating the company's commitment to compliance with the most rigorous global regulatory and quality standards. "We are proud of the robust systems our team has built, ensuring stringent control over development and manufacturing processes," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "This certification demonstrates our ongoing ability to meet exacting regulatory requirements as we continue to achieve clinical and developmental milestones
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
Live Leadership Updates
SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharmaceutical development, clinical trials, and regulatory strategies. "Dr. Kelman is an outstanding addition to our team as we progress our programs into later stages of development and prepare to enter the clinic with the BT-600 program, which is designed to deliver our unique formulation of tofacitinib to the colon using our proprietary GItrac™ technology," said Adi Mohanty, Chief Executive Officer of Bio
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutics, announced today the appointment of Dr. Bruce Sands as board chair of its Clinical Advisory Board for Inflammatory Bowel Disease (IBD), which also includes leading IBD researchers Dr. Geert D'Haens, Dr. Brian Feagan, and Dr. Séverine Vermeire. The clinical advisory board provides strategic guidance on clinical development of Biora's Targeted Therapeutics pipeline. "Targeted drug delivery to the large intestine has the potential to enable new therapeutic approaches, including combination therapy, for IBD patients," said Dr. Bruce Sands. "I'm pleased to
This live feed shows all institutional transactions in real time.
SC 13G - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13G - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13G/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
Live finance-specific insights
Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The company will not host a conference call. "We've made much faster progress than anticipated developing a smaller BioJet device that is highly desired by pharma companies," said A
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets. Conference Call and Webcast InformationDate: Thursday, November 14, 2024Time: 4:30 PM Eastern time / 1:30 PM Pacific timeConference Call: Domestic 1-877-423-9813International 1-201-689-8573Conference ID 13749254Live Webcast: https://investors.bioratherapeutics.com/events-presentations A replay will
Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from existing investors supported by BT-600 results and progress toward BioJet™ partnership Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. "Research shows that ulcerative colitis patients with higher drug exposur
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the second quarter ended June 30, 2024. Company management will host a webcast and conference call on Monday, August 12, 2024, after the close of financial markets. Conference Call and Webcast InformationDate:Monday, August 12, 2024Time:4:30 PM Eastern time / 1:30 PM Pacific timeConference Call:Domestic 1-877-423-9813 International 1-201-689-8573 Conference ID 13747616Call me for instant telephone accessLive Webcast:https://investors.bioratherapeutics.com/events-presenta
Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented at DDW on May 19 Partnering process for the BioJet oral delivery platform is progressing well Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. "We were gratified to see the excellent int
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the first quarter ended March 31, 2024. The company's management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets. Conference Call and Webcast Information Date: Wednesday, May 15, 2024 Time: 4:30 PM Eastern time / 1:30 PM Pacific time Conference Call: Domestic 1-877-423-9813 International 1-201-689-8573 Conference ID 13746163 Call me for instant telephone access Live Webcast: https://investors.bior
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood Remainder of BT-600 clinical trial progressing well and on schedule Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2023. "We are thrilled by t
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the fourth quarter and full year ended December 31, 2023. The company's management will host a webcast and conference call on Tuesday, March 26, 2024, after the close of financial markets. Conference Call and Webcast InformationDate:Tuesday, March 26, 2024Time:4:30 PM Eastern time / 1:30 PM Pacific timeConference Call:Domestic 1-877-423-9813 International 1-201-689-8573 Conference ID 13744533 Call me for instant telephone accessLive Webcast:https://investors.bio
NaviCap™ Targeted Oral Delivery platform advancing toward initiation of phase 1 clinical trial by year end Pharma collaborations accelerate for the BioJet™ Systemic Oral Delivery platform, which shows potential for liver-targeted delivery of large molecules Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2023. The company's management will host a webcast and conference call on Monday, November 13, 2023, after the close of financial markets at 4:30 PM Eastern time / 1:30 PM Pacific time. The live call may be accessed by dialing 1-877-423-9813 (domestic) or 1-201-689-8573 (international) and entering the conference code: 13741259. A live webcast will be available via the Investor Relations section of the company website, wit